BlueSky Immunotherapies Competitors and Similar CompaniesClear all

BlueSky Immunotherapies's competitors and similar companies include ImmuneSensor Therapeutics, Eikonoklastes Therapeutics, CalciMedica and Camurus.

	BlueSky Immunotherapies BlueSky Immunotherapies (also known as BlueSky Vaccines) is a company focusing on developing next-generation immunotherapies against infectious diseases and cancer.	ImmuneSensor Therapeutics ImmuneSensor Therapeutics is a company aiming to treat cancer and autoimmune diseases.	Eikonoklastes Therapeutics Eikonoklastes Therapeutics is a developer of tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases.	CalciMedica CalciMedica (formerly known as Graybug Vision) is a biotechnology company that develops calcium release-activated calcium (CRAC) channel inhibitors.	Camurus Camurus is a research-based pharmaceutical company that develops medicines for severe and chronic conditions.
Founding Date	Founding Date 2017	Founding Date 2014	Founding Date 2019	Founding Date 2007	Founding Date 1991
Type	Type Private	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Manufacturing & Industrial biotech drug development oncology pharma	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Wien, AT HQ	Locations Dallas, US HQ	Locations Cincinnati, US HQ	Locations La Jolla, US HQ	Locations Lund, SE HQ Sydney, AU Mannheim, DE Duxford, GB
Employees	Employees 8	Employees 11	Employees 8	Employees 1614% increase	Employees 265
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 42.4 m	Valuation ($) 3.4 b
Financial
Net income	Net income N/A	Net income N/A	Net income N/A	Net income ($29.6m) (FY, 2025)	Net income kr735.6m (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 1.1m	Total funding raised $ 74.5m	Total funding raised N/A